Erschienen in:
08.08.2023 | ASO Author Reflections
ASO Author Reflections: National Implementation of Sentinel Lymph Node Biopsy in Early-Stage Endometrial Cancer
verfasst von:
S. Cabrera, MD, PhD, Spain-GOG and MULTISENT Study Group
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 12/2023
Einloggen, um Zugang zu erhalten
Excerpt
Endometrial cancer is the most commonly diagnosed gynecological malignancy in developed countries, and surgery is an essential component of its treatment. In early stages, surgery is often curative and enables proper risk assessment for personalized adjuvant therapies if necessary.
1 The role of lymph node staging in this context has been a topic of debate for many years, as it is considered a procedure with potential morbidity and no proven survival benefit.
2 Therefore, it was reserved for patients at higher risk of nodal involvement on the basis of preoperative pathological and radiological characteristics (histology, myometrial infiltration, cervical invasion). The introduction of sentinel lymph node (SLN) biopsy as an accurate staging tool for early stage endometrial cancer,
3 along with prospective evidence from trials including patients at low, intermediate, and high risk of nodal involvement,
3‐5 has revolutionized the surgical management of these patients. This technique allows for the detection of nodal disease including the identification of micrometastases and isolated tumor cells through ultrastaging, which may be missed by standard pathology analysis.
3 However, the widespread use of this technique in a clinical setting may adversely affect its performance. …
